Abstract 4097
Background
Neuregulin 1 (NRG1) is a growth factor that binds HER3/4 and activates ErbB signalling pathways. NRG1 fusions function as oncogenic drivers and represent a potential therapeutic target across tumour types. Afatinib, an ErbB-family blocker, may be a treatment option for some patients (pts) with NRG1 fusion-positive (NRG1+) tumours, as supported by preclinical evidence and published case reports (Table).Table: 1969P
Patient | Tumour type | NRG1 fusion partner | Best response | Duration of response (months) | Reference |
---|---|---|---|---|---|
i | Non-mucinous lung ADC | SLC3A2 | PR | 12 | Gay, et al. J Thoracic Oncol 2017 |
ii | Non-mucinous lung ADC | SDC4 | PR | 12 | Jones, et al. Ann Oncol 2017 |
iii | IMA | CD74 | PR | 10 | Gay, et al. J Thoracic Oncol 2017 |
iv | IMA | CD74 | PR | 6.5 | Cheema, et al. J Thoracic Oncol 2017 |
v | IMA | CD74 | SD | 3 | Drilon, et al. Cancer Discov 2018 |
vi | IMA | SDC4 | PD | - | Drilon, et al. Cancer Discov 2018 |
vii | IMA | CD74 | PD | - | Drilon, et al. Cancer Discov 2018 |
viii | Cholangiocarcinoma | ATP1B1 | PR | 8 | Jones, et al. Ann Oncol 2017 |
ix | Pancreatic ADC | ATP1B1 | PR | 3 | Heining, et al. Cancer Discov 2018 |
x | Ovarian cancer | CLU | SD | - | Murumagi. AACR 2019, abs 2945 |
ADC, adenocarcinoma; IMA, invasive mucinous lung adenocarcinoma; PD, progressive disease; PR, partial response; SD, stable disease
Methods
We report clinico-pathological and molecular characteristics of seven previously unreported cases of afatinib-treated NRG1+ tumours.
Results
Pt 1, 70 yo female, never-smoker with pan-wildtype, non-mucinous lung adenocarcinoma (ADC) received 15th-line afatinib for 24 mos (PR). An NRG1 fusion was subsequently identified. The pt was re-challenged with afatinib (PR, 3 mos) before switching to atezolizumab (PD). Pt 2, 66 yo female, never-smoker with metastatic (m) non-mucinous lung ADC. CD74-NRG1 fusion was identified, and 5th-line afatinib initiated. PR is ongoing after 14 mos. Pt 3, 68 yo male, >20 pack-yr smoking history with non-mucinous lung ADC. SDC4-NRG1 fusion was identified and 2nd-line afatinib initiated. Best response: SD, 4 mos. Pt 4, 43 yo female, non-smoker with advanced invasive mucinous lung ADC. CD74-NRG1 fusion was identified and 3rd-line afatinib initiated; PR is ongoing. Pt 5, 69 yo male, with KRAS-mutated m-colorectal cancer. Following a right hemicolectomy and liver/lung metastasectomies, a novel POMK-NRG1 fusion was detected and afatinib initiated (SD, 4 mos; treatment ongoing). Pts 6 and 7, male (54 & 59 yo) with KRAS WT, m-pancreatic cancers. Following PD on chemotherapy, APP-NRG1 and ATP1B1-NRG1 fusions, respectively, were detected and afatinib initiated. Pt 6 had a PR for 5 mos; treatment ongoing. Pt 7 had a PR for 5.5 mos.
Conclusions
These findings add to a growing body of evidence suggesting that afatinib is a potential treatment option for pts with NRG1+ tumours. Prospective study is ongoing in the Drug Rediscovery Protocol trial (DRUP; NCT02925234).
Clinical trial identification
N/A
Editorial acknowledgement
Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Christina Jennings, of GeoMed, an Ashfield company, part of UDG Healthcare plc.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
S.V. Liu: Advisory / Consultancy: Apollomics; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Celgene; Advisory / Consultancy: G1 Therapeutics; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: Heron; Advisory / Consultancy: Ignyta; Advisory / Consultancy: Janssen; Advisory / Consultancy: Lilly; Advisory / Consultancy: Regeneron; Advisory / Consultancy: Takeda/Ariad; Advisory / Consultancy: Tempus; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Taiho. M. Duruisseaux: Honoraria (self): Roche; Honoraria (self): Takeda; Honoraria (self): Pfizer; Honoraria (self): Novartis; Honoraria (self): AstraZeneca; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Merck Sharp and Dohme; Honoraria (self): AbbVie; Honoraria (self): Boerhinger Ingelheim. K. Tolba: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: Boerhinger Ingelheim; Honoraria (self): Merck; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Foundation One. Y. Goto: Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Eli Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Chugai; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Taiho Pharmaceuticals; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boerhinger Ingelheim; Speaker Bureau / Expert testimony, Research grant / Funding (self): Ono Pharmaceuticals; Speaker Bureau / Expert testimony, Research grant / Funding (self): Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Pfizer; Speaker Bureau / Expert testimony: Merck Sharp and Dohme; Speaker Bureau / Expert testimony: Shionogi Pharmaceuticals; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Novartis; Advisory / Consultancy: GSK; Research grant / Funding (self): AbbVie; Research grant / Funding (self): Dai-ichi Sankyo; Advisory / Consultancy: Kyorin. B.A. Weinberg: Travel / Accommodation / Expenses: Boehringer Ingelheim. D.J. Renouf: Honoraria (self): Celgene; Honoraria (self): Servier; Honoraria (self): Taiho; Honoraria (self): Ipsen; Honoraria (self): Bayer. R.C. Doebele: Advisory / Consultancy, Shareholder / Stockholder / Stock options, Licensing / Royalties: Rain Therapeutics; Honoraria (self): Guardant; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Trovagene; Advisory / Consultancy, Licensing / Royalties: Ariad; Advisory / Consultancy: Takeda; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy, Research grant / Funding (self), Licensing / Royalties: Ignyta; Advisory / Consultancy, Research grant / Funding (self), Licensing / Royalties: Loxo; Research grant / Funding (self): Mirati; Licensing / Royalties: Abbott Molecular; Licensing / Royalties: GVKbio; Licensing / Royalties: Chugai; Licensing / Royalties: Genentech; Licensing / Royalties: Foundation Medicine; Licensing / Royalties: Black Diamond. R.F. Schlenk: Research grant / Funding (self): Boehringer Ingelheim. P.K. Cheema: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Takeda; Honoraria (self), Advisory / Consultancy: Genomic Health; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Merck. J. Cadranel: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Lilly; Advisory / Consultancy: Merck Sharp and Dohme; Advisory / Consultancy, Research grant / Funding (self): Novartis; Advisory / Consultancy, Research grant / Funding (self): Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Takeda. M.R. Jones: Full / Part-time employment: Qiagen Inc. A.E. Drilon: Honoraria (self): Medscape; Honoraria (self): OncLive; Honoraria (self): PeerVoice; Honoraria (self): Physicians Education Resources; Honoraria (self): Tyra Biosciences; Honoraria (self): Targeted Oncology; Honoraria (self): MORE Health; Honoraria (self): Research to Practice; Honoraria (self): Foundation Medicine; Honoraria (self): Peerview; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Genentech/Roche; Honoraria (self), Advisory / Consultancy: Bayer; Advisory / Consultancy: Ignyta; Honoraria (self): Loxo; Advisory / Consultancy: TP Therapeutics; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Blueprint Medicines; Advisory / Consultancy: Takeda; Advisory / Consultancy: Helsinn Therapeutics; Advisory / Consultancy: BeiGene; Advisory / Consultancy: Hengrui Therapeutics; Advisory / Consultancy: Exelixis; Travel / Accommodation / Expenses, Other: Wolters Kluwer. L.A. Muscarella: Honoraria (self): AstraZeneca; Honoraria (self): Roche; Honoraria (self): Boehringer Ingelheim. A. Cseh: Full / Part-time employment: Boehringer Ingelheim; Shareholder / Stockholder / Stock options, Husband: Mylan. F. Solca: Full / Part-time employment: Boehringer Ingelheim RCV GmbH & Co KG. J.J. Laskin: Honoraria (self), Research grant / Funding (self): Roche Canada; Honoraria (self): Boehringer Ingelheim Canada; Honoraria (self): AstraZeneca Canada; Research grant / Funding (self): Pfizer Canada. All other authors have declared no conflicts of interest.
Resources from the same session
4900 - Molecular profiling and prognostic significance of TP53 mutations in Diffuse Large B Cell Lymphoma: identifying a high-risk subgroup
Presenter: Yuan-Kai Shi
Session: Poster Display session 3
Resources:
Abstract
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract